50 results found.

Hepatitis C Clinical Trial

Hologic, Inc. - Recruiting 18 years or older.
- Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay.

Primary Sclerosing Cholangitis (PSC) Clinical Trial using Simtuzumab; Placebo

Gilead Sciences - Recruiting 18 years to 70 years.
- A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC).
Simtuzumab; Placebo

Chronic Idiopathic Constipation Clinical Trial using YKP10811; Placebo

SK Life Science - Recruiting 18 years to 65 years.
- .
YKP10811; Placebo

Liver Diseases, Hepatocellular Cancer, Endstage Liver Disease, or Clinical Trial using donor pain management/ Pre-operative OR Set-up

Northwestern University - Recruiting 21 years to 60 years.
- A2ALL-Patients Safety System Improvements in Living Donor Liver Transplant.
donor pain management/ Pre-operative OR Set-up

Liver Disease, or Renal Disease Clinical Trial

Baylor Research Institute - Recruiting 18 years or older.
- Quantitative Evaluation of Liver and Kidney Disease With Liver and Kidney Elastography Measurements in Liver Transplant Recipients Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine.

Liver Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Physiology of Fatigue in Patients With Chronic Liver Disease.

Sickle Cell Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Evaluation of Sickle Cell Liver Disease.

Alcohol-related Liver Disease Clinical Trial

Northwestern University - Recruiting 18 years or older.
- Alcohol Biomarkers in Post-Liver Transplant Patients.

Hepatitis C, Liver Disease Clinical Trial using DEB025 200mg; DEB025 300mg; DEB025 400mg

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment na‹ve Patients.
DEB025 200mg; DEB025 300mg; DEB025 400mg

Chronic Liver Disease Clinical Trial

Association HGE CHU Bordeaux Sud - Recruiting 18 years or older.
- Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up..

Chronic HCV Infection Clinical Trial using LDV/SOF; RBV

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant.
LDV/SOF; RBV

Non-Alcoholic Steatohepatitis (NASH) Clinical Trial using Simtuzumab 75 mg; Simtuzumab 125 mg; Placebo

Gilead Sciences - Recruiting 18 years to 60 years.
- A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety, and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2) in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH).
Simtuzumab 75 mg; Simtuzumab 125 mg; Placebo

Hepatitis C Clinical Trial using DCV/ASV/BMS-791325

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C.
DCV/ASV/BMS-791325

Liver Cancer, or Metastatic Cancer Clinical Trial using capecitabine; yttrium Y 90 glass microspheres

Northwestern University - Recruiting 18 years or older.
- Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver.
capecitabine; yttrium Y 90 glass microspheres

Crohn's Disease Clinical Trial using RHB-104; Placebo

RedHill Biopharma Limited - Recruiting 18 years to 65 years.
- A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease.
RHB-104; Placebo

Ulcerative Colitis Clinical Trial using tofacitinib; Placebo

Pfizer - Recruiting 18 years or older.
- Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
tofacitinib; Placebo

Progressive Familial Intrahepatic Cholestasis (PFIC) Clinical Trial using LUM001

Lumena Pharmaceuticals, Inc. - Recruiting 12 Months to 18 years.
- Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis.
LUM001

Radiofrequency Ablation, Liver Abscesses -Staphylococcus Infectio Clinical Trial using RFA - Radiofrequency Ablation; Scans - Liver; Liver; Drawn

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Radiofrequency Ablation (RFA) for the Treatment of Liver Abscesses in Patients With Chronic Granulomatous Disease.
RFA - Radiofrequency Ablation; Scans - Liver; Liver; Drawn

Alagille Syndrome Clinical Trial using LUM001

Lumena Pharmaceuticals, Inc. - Recruiting 2 years or older.
- A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome.
LUM001

Portal Hypertension, or Liver Disease Clinical Trial using Volumetric Flow in TIPS

University of Michigan - Recruiting 18 years or older.
- 3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts.
Volumetric Flow in TIPS

Chronic HCV Infection Clinical Trial using SOF/LDV FDC; RBV

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant.
SOF/LDV FDC; RBV

Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD Clinical Trial using Transient elastography, acoustic radiation force impulse, magnetic resonance elastography

Centre hospitalier de l'Universit‚ de Montr‚al (CHUM) - Recruiting 18 years or older.
- Comparison of Magnetic Resonance and Ultrasound Elastography With Liver Biopsy for Noninvasive Staging of Liver Fibrosis.
Transient elastography, acoustic radiation force impulse, magnetic resonance elastography

Fatty Liver, or Steatohepatitis Clinical Trial using Rifaximin

Bezmialem Vakif University - Recruiting 18 years to 70 years.
- The Efficacy of Antibiotic Rifaximin on the Lipopolysaccharides (LPS) and Related Cytokine Levels in Non Alcoholic Fatty Liver Disease Patients.
Rifaximin

Thrombocytopenia Associated With Liver Disease Clinical Trial using avatrombopag (lower baseline platelet count); placebo (lower baseline platlet count); avatrombopag (higher baseline platelet count); placebo (higher baseline platelet count)

Eisai Inc. - Recruiting 18 years or older.
- A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure.
avatrombopag (lower baseline platelet count); placebo (lower baseline platlet count); avatrombopag (higher baseline platelet count); placebo (higher baseline platelet count)

CHB Patients Without Significant Alcohol Consumption or Other Kno Clinical Trial

Seoul National University Boramae Hospital - Recruiting 20 years to 80 years.
- Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease.

Chronic Liver Disease, Hazardous Alcohol Use, Type 2 Diabetes, or Clinical Trial using Fibrosis Biomarkers

University of Nottingham - Recruiting 18 years or older.
- The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers.
Fibrosis Biomarkers

Biliary Liver Cirrhosis,, Hemochromatosis, Hepatitis, Hepatolenti Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Evaluation of Patients With Liver Disease.

Chronic Hepatitis C Virus, or Non Alcoholic Fatty Liver Disease Clinical Trial using normocaloric low cholesterol diet

University of Roma La Sapienza - Recruiting 40 years to 70 years.
- Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano.
normocaloric low cholesterol diet

Hepatitis, HIV, or Liver Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Natural History of Liver Disease in a Cohort of Participants With Hepatitis B and/or Hepatitis C With or Without HIV Infection.

Ulcerative Colitis Clinical Trial using Placebo; CP690,550

Pfizer - Recruiting 18 years or older.
- A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis.
Placebo; CP690,550

Morbid Obesity, or Non-alcoholic Fatty Liver Disease Clinical Trial

University Health Network, Toronto - Recruiting 18 years or older.
- Role of Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Pre and Post bAriatric Surgery.

Chronic Hepatitis C Clinical Trial using Sofosbuvir; RBV; PEG

Gilead Sciences - Recruiting 18 years or older.
- An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies.
Sofosbuvir; RBV; PEG

Total Parenteral Nutrition-induced Cholestasis Clinical Trial using Soybean oil based emulsion; Soybean oil based emulsion+Fish oil based emulsion

University Health Network, Toronto - Recruiting 18 years or older.
- Effect of n-3 Polyunsaturated Fatty Acid Lipid Emulsion on Parenteral Nutrition Associated Liver Disease.
Soybean oil based emulsion; Soybean oil based emulsion+Fish oil based emulsion

Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coi Clinical Trial using Shear Wave sonoelastography

Massachusetts General Hospital - Recruiting 18 years or older.
- Evaluate the Utility of Shear Wave Sonoelastography as a Tool to Measure Liver Fibrosis Grade..
Shear Wave sonoelastography

Nonalcoholic Fatty Liver Disease Clinical Trial using MB12066 200mg; Placebo

KT&G Life Sciences Corp - Recruiting 20 years or older.
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis.
MB12066 200mg; Placebo

Nonalcoholic Fatty Liver Disease Clinical Trial using Anthocyanin; Placebo

Shaoguan University - Recruiting 18 years to 65 years.
- Effects of Purified Anthocyanin on Oxidative and Inflammatory Markers in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial.
Anthocyanin; Placebo

Psoriasis, or Nonalcoholic Fatty Liver Disease Clinical Trial

George Washington University - Recruiting 18 years to 80 years.
- A Case Control Study to Evaluate the Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Among Patients With Psoriasis.

Obesity, or Non-alcoholic Fatty Liver Disease (NAFLD) Clinical Trial using Hypocaloric diet

University Hospital, Geneva - Recruiting 18 years to 60 years.
- Effect of Dietary Intervention on Intestinal Microbiota in Patients With Non-alcoholic Fatty Liver Disease.
Hypocaloric diet

Polycystic Liver Disease (PLD):, Polycystic Kidney, Autosomal Dom Clinical Trial using Ursodeoxycholic Acid

Radboud University - Recruiting 18 years to 80 years.
- An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease.
Ursodeoxycholic Acid

Non-alcoholic Fatty Liver Disease, or Metabolic Syndrome Clinical Trial

Washington University School of Medicine - Recruiting 18 years to 55 years.
- Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (10-0188, Pfizer).

Non Alcoholic Fatty Liver Disease Clinical Trial using Px-104

Phenex Pharmaceuticals AG - Recruiting 18 years to 70 years.
- A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients.
Px-104

Liver Disease Clinical Trial using Tacrolimus and Sirolimus; Tacrolimus

Foundation for Liver Research - Recruiting 18 years to 70 years.
- A Multicenter Randomized in Primary Livertransplantation Comparing Longterm Renal Function in Recipients Treated With Tacrolimus Alone and Recipients Treated With a Combination Tacrolimus and Sirolimus.
Tacrolimus and Sirolimus; Tacrolimus

Fatty Liver Clinical Trial using Resveratrol; Placebo

University of Aarhus - Recruiting 18 years to 70 years.
- Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds, Study 3.
Resveratrol; Placebo

Transfusion-related Acute Lung Injury, Chronic Liver Disease, or Clinical Trial

University of Colorado, Denver - Recruiting 18 years to 85 years.
- Endogenous Heparinoid Interference With Coagulation on Thromboelastogram as a Predictive Biomarker for Transfusion Related Acute Lung Injury (TRALI).

Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominan Clinical Trial using Pasireotide LAR; Placebo

Mayo Clinic - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease.
Pasireotide LAR; Placebo

Crohn's Disease, or Perianal Fistulas Clinical Trial using Hyperbaric oxygen

Assaf-Harofeh Medical Center - Recruiting 18 years to 70 years.
- Prospective Open-label Study of the Efficacy of the Addition of Hyperbaric Oxygen to the Treatment of Patients With Perianal Fistulas Already Treated With TNF Alpha Blockers.
Hyperbaric oxygen

Metabolic Syndrome, Non Alcoholic Fatty Liver Disease, or Insulin Clinical Trial using glucomannan; lifestyle intervention

Bambino Ges— Hospital and Research Institute - Recruiting 4 years to 16 years.
- Study of the Efficacy and Tolerability of Glucomannan on Children Affected by NAFLD.
glucomannan; lifestyle intervention

Liver Disease, or Liver Transplant Clinical Trial

Medical College of Wisconsin - Recruiting N/A to 18 years.
- Pediatric Liver Disease and Liver Transplant Database.

Hepatitis C, Hepatitis B, Autoimmune Hepatitis, Liver Cirrhosis, Clinical Trial

University Health Network, Toronto - Recruiting 18 years to 85 years.
- Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease.

Liver Diseases Clinical Trial using Choline Chloride

FDA Office of Orphan Products Development - Recruiting 21 years to 74 years.
- Prevention of TPN-Associated Hepatic Steatosis: A Placebo Controlled Trial.
Choline Chloride